Topics

UCB to strengthen myasthenia gravis offerings through $2.1bn acquisition of Ra Pharmaceuticals

15:40 EDT 11 Oct 2019 | Elsevier Business Intelligence

Complement-mediated disease drug developer Ra Pharmaceuticals Inc. agreed to be acquired by UCB Group, which will pay $48 per...

Original Article: UCB to strengthen myasthenia gravis offerings through $2.1bn acquisition of Ra Pharmaceuticals

NEXT ARTICLE

More From BioPortfolio on "UCB to strengthen myasthenia gravis offerings through $2.1bn acquisition of Ra Pharmaceuticals"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...